{"title":"Ammonia: a metabolic checkpoint for Treg potency.","authors":"Ali Valipour Motlagh, Eyad Elkord, Weiwei Dai","doi":"10.1016/j.trecan.2026.02.002","DOIUrl":null,"url":null,"abstract":"<p><p>Ammonia acts as a metabolic checkpoint fueling regulatory T cells (Tregs). Gu et al. demonstrate that utilizing argininosuccinate lyase-linked survival buffering and a FOXP3-spermine-PPARγ axis for mitochondrial reinforcement allows Tregs to convert toxic waste into suppressive power, driving tumor immune evasion and immunotherapy resistance.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"307-309"},"PeriodicalIF":21.6000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2026.02.002","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Ammonia acts as a metabolic checkpoint fueling regulatory T cells (Tregs). Gu et al. demonstrate that utilizing argininosuccinate lyase-linked survival buffering and a FOXP3-spermine-PPARγ axis for mitochondrial reinforcement allows Tregs to convert toxic waste into suppressive power, driving tumor immune evasion and immunotherapy resistance.
期刊介绍:
Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine.
Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.